[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100376726":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":32,"responsibleParty":52,"collaborators":11,"id":54,"slug":11,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Institut Paoli-Calmettes","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"non-metastatic colon cancer","EXPERIMENTAL",null,[13],"Biological: analysis of BTN and BTNL status",{"label":15,"type":10,"description":11,"interventionNames":16},"metastatic colon cancer",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"BIOLOGICAL","analysis of BTN and BTNL status","analysis of BTN and BTNL expression in colon cancer and hepatic metastasis",[15,9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Jihane PAKRADOUNI, PharmD,PhD","CONTACT","04 91 22 37 78","drci.up@ipc.unicancer.fr",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":28},"Laurie-Anne GOUTY, PhD","33491223778",[33],{"facility":5,"status":34,"city":35,"state":11,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Marseille","13273","France",{"type":39,"coordinates":40},"Point",[41,42],5.38107,43.29695,{"lat":42,"lon":41},[45,47,49],{"name":46,"role":26,"phone":31,"phoneExt":11,"email":28},"Jihane PAKRADOUNI, PharmD, PhD",{"name":30,"role":26,"phone":48,"phoneExt":11,"email":28},"0491223778",{"name":50,"role":51,"phone":11,"phoneExt":11,"email":11},"Hélène MEILLAT","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100376726",false,"NCT04185272","Butyrophilins Role in Colon Cancer","Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation","Inclusion Criteria:\n\n* Patient is older than 18 years old,\n* Signed participation consent,\n* Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.\n* Performance Status (PS) 0 or 1\n* affiliated to the social security or beneficiary\n\nExclusion Criteria:\n\n* Rectal cancer, colon cancer recurrence\n* Emergency of colon cancer Surgery\n* History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)\n* Patient who received neoadjuvant therapy other than chemotherapy\n* Patient treated with immune-suppressors or long-course corticosteroids \\\u003C12 months\n* Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding,\n* Person in urgent situation, person under legal protection measure, or unable to express his \u002F her consent,\n* Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons","ALL","18 Years",{"count":63,"type":64},200,"ESTIMATED","INTERVENTIONAL",[67],"NA","quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer",[70],"Colonic Cancer","2025-06-13",{"date":73,"type":74},"2025-06-15","ACTUAL",{"date":76,"type":74},"2020-06-30",{"date":78,"type":64},"2028-06",{"name":5,"class":6},1]